Vaccine CDMO Market Key Players, Trends & Forecast to 2030

The global vaccine CDMO market is projected to grow at an annual rate of 8% over the next five years. Key drivers include the rising demand for vaccines, expanding collaborations between biopharmaceutical companies and government bodies with CDMOs, advancements in vaccine production technologies, and a growing need for specialized CDMO services to support emerging vaccine innovations. Additionally, increased private and public investment in vaccine CDMOs, along with a rising trend of outsourcing to cut costs and speed up time-to-market, are fueling market growth.

Download Sample Copy: https://meditechinsights.com/vaccine-cdmo-market/request-sample/

A Vaccine Contract Development and Manufacturing Organization (CDMO) offers outsourced services for the development, production, and commercialization of vaccines. These organizations partner with pharmaceutical and biotech companies, providing comprehensive solutions that span process development, drug substance manufacturing, fill-finish, packaging, and regulatory compliance. Vaccine CDMOs specialize in cutting-edge technologies, including mRNA, viral vectors, recombinant proteins, and inactivated vaccines, helping clients scale production quickly and efficiently. They are vital in expediting vaccine development, particularly during global health crises, by offering flexible, high-capacity manufacturing capabilities.

Competitive Landscape Analysis

The global vaccine CDMO market is marked by the presence of established and emerging market players such as Lonza Group, Thermo Fisher Scientific, Catalent, Inc, Samsung Biologics, CordenPharma, WuXi Vaccines, Recipharm AB, ICON plc, FUJIFILM Diosynth Biotechnologies, and Curia Global, Inc.; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.

Rising Vaccine Demand Boosts Market Growth
The growing demand for vaccines—driven by infectious disease outbreaks, expanding immunization programs, and advancements in mRNA technology—is accelerating the vaccine CDMO market. Biopharma companies are increasingly outsourcing manufacturing to CDMOs to scale production, cut costs, and navigate complex regulatory landscapes. The success of COVID-19 mRNA vaccines has significantly boosted demand for CDMOs with expertise in lipid nanoparticle (LNP) formulation and cold chain logistics. Additionally, global vaccine initiatives and government partnerships are securing long-term contracts for CDMOs, prompting major players to ramp up manufacturing capacity to meet the escalating global vaccine demand.

Download Sample Copy: https://meditechinsights.com/vaccine-cdmo-market/request-sample/

Technological Advancements Fuel Market Expansion
Innovations in vaccine manufacturing technologies, including mRNA, viral vectors, cell-based production, and single-use bioreactors, are driving growth in the Vaccine CDMO market. These advancements require specialized knowledge and infrastructure, pushing biopharma companies to outsource production to CDMOs with cutting-edge capabilities. Breakthroughs in mRNA vaccines, particularly in LNP formulation and enzymatic synthesis, have further increased demand for CDMO services. Meanwhile, automation, continuous manufacturing, and AI-driven process optimization are enhancing production efficiency. Leading CDMOs are focusing on next-generation vaccine technologies, accelerating global vaccine availability and commercialization.

Global Vaccine CDMO Market Segmentation

This report by Medi-Tech Insights provides the size of the global vaccine CDMO market at the regional- and country-level from 2023 to 2030. The report further segments the market based on vaccine type, phase, end user.

Market Size & Forecast (2023-2030), By Vaccine Type, USD Million

• mRNA Vaccines
• Viral Vector Vaccines
• Recombinant Protein Vaccines
• Inactivated & Live-Attenuated Vaccines
• Conjugate & Toxoid Vaccines
• DNA Vaccines
• Others

Market Size & Forecast (2023-2030), By Phase, USD Million

• Pre-clinical
• Clinical
• Commercial

Market Size & Forecast (2023-2030), By End User, USD Million

• Biopharmaceutical & Vaccine Developers
• Government & Public Health Agencies
• Others

Market Size & Forecast (2023-2030), By Region, USD Million

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa

Browse Report: https://meditechinsights.com/vaccine-cdmo-market/

About Medi-Tech Insights;

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde

Associate, Medi-Tech Insights

+32 498 86 80 79

info@meditechinsights.com